Olivier Negre, Ph.D. developed his expertise in preclinical research and drug development through more than 20 years of experience in biotherapies. After working on recombinant vaccines with Bioprotein Technologies, he joined bluebird bio and contributed for 15 years to the development of the first approved gene therapy for beta-thalassemia. Scientist and Team Leader in Paris, France and became Director for Translational Research in Cambridge MA, USA. Back to France he co-founder Biotherapy Partners and participated in the HEC Challenge Plus training program. He is board member of the French Society of Gene and Cell Therapy and President of the think-tank Gene and Cell Therapy Institute (G&CTI). Currently Chief Scientific Officer at Smart Immune, he contributes to develop a new T-cell platform with applications in the field of hematopoietic stem cell transplant and cellular immuno-oncology.